Navigation Links
Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011
Date:2/4/2011

to 40 patients and complete enrollment in the second half of calendar year 2011. We also plan to evaluate the safety of PCI-32765 in combination with several other common therapies in CLL and expect to begin enrollment in Q2 of calendar year 2011.-Diffuse Large B-Cell Lymphoma (DLBCL) Research has demonstrated that there are 2 distinct molecular subtypes in diffuse large B-cell lymphoma (ABC and GCB).  Activated B-cell, or ABC, is the poorer prognostic subtype and is characterized by activation of the B-cell receptor signaling pathway. Our Phase II program will evaluate 2 separate cohorts of patients with relapsed or refractory DLBCL who will receive single agent PCI-32765, those lymphoma patients with ABC and those with germinal center B-cell (GCB), the other molecular subtype. This study will evaluate safety and efficacy in approximately 60 patients. We anticipate that enrollment will begin during the first half of 2011. In parallel, we are also developing a Phase II safety trial combining PCI-32765 with chemotherapy in patients with relapsed or refractory DLBCL.


  • Abstract submitted to the 47th Annual Meeting of the American Society of Clinical Oncology (June 3 – 7, 2011) based on the Phase IB/II study data, evaluating safety and efficacy of administering the Btk Inhibitor, PCI-32765 as a single agent in CLL/SLL patients

  • Poster presentation at the 2011 GI Cancers Symposium of first in human Phase I results of Factor VIIa Inhibitor, PCI-27483 In the Phase I portion of the study, ascending repeated doses of PCI-27483 (dosages ranging from 0.8 to 1.5 mg/kg) were evaluated in 8 patients with pancreatic cancer receiving concomitant gemcitabine chemotherapy. Among the 5 patients in Phase I considered evaluable, all 5 had stable disease at week 12 and opted to extend treatment with PCI-27483. Three of the 5 patients have a progression free survival > / = 30 weeks (7 months). None
    '/>"/>


  • SOURCE Pharmacyclics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related biology technology :

    1. Pharmacyclics Announces Date of Fourth Quarter and Fiscal Year End 2009 Conference Call
    2. Pharmacyclics to Present and Webcast at Upcoming Life Sciences Investor Conferences
    3. Pharmacyclics, Inc. Rights Offering Oversubscribed
    4. Pharmacyclics Announces Subscription Price for Rights Offering
    5. Pharmacyclics to Present at the 8th Annual Needham and Company Life Sciences Conference
    6. Pharmacyclics Files Registration Statement for Rights Offering
    7. Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
    8. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
    9. Pharmacyclics Secures $5.0 Million in Debt Financing
    10. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
    11. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/5/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/x5gjj3/clinical ) ... Laboratory, Molecular Diagnostics and Genomic Testing Services Market ... Version" report to their offering. ... molecular diagnostics and pharmacogenics hold the promise of ... is moving out of the national and regional ...
    (Date:5/5/2015)... 2015   Tocagen Inc. , a clinical-stage ... Parkinson , M.D., a venture partner at New ... board of directors of Tocagen. Dr. Parkinson has ... clinical development, including leading clinical activities at Amgen ... the cancer therapeutics Gleevec®, Femara®, Zometa®, Kepivance® and ...
    (Date:5/5/2015)... Synedgen Inc. is pleased to announce ... Manager. , Dr. Nguyen brings to Synedgen critical regulatory ... company as it moves forward in the FDA regulatory ... two years. Dr. Nguyen will lead the management of ... documents that must be completed in order to initiate ...
    (Date:5/4/2015)... /PRNewswire/ - JSS Medical Research Inc., a Montreal ... the acquisition of Max Neeman International (MNI), with head office in ... located in Ahmedabad, Bangalore , Chennai ... subsidiary, a regional office is located North Carolina, USA ... the recent equity investment transaction into JSS with Capital Croissance PME ...
    Breaking Biology Technology:Global Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecast 2015 to 2019 2Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 2Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 3Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 4Synedgen Announces the Appointment of Regulatory Affairs Manager 2JSS Medical Canada widens its global presence across Asia/Pacific region 2JSS Medical Canada widens its global presence across Asia/Pacific region 3JSS Medical Canada widens its global presence across Asia/Pacific region 4
    ... CardioInsight Technologies Inc., the leading developer of ... of Jim Bullock as Chairman of the Company,s ... ) Mr. Bullock is a ... has served as Chief Executive Officer of Atritech, ...
    ... a biotechnology research company and leading developer of human ... of new drug compounds, has been invited to present ... Vascular Biology (ATVB) conference .  The conference will be ... South Michigan Avenue in Chicago, Illinois. ...
    ... ability to control the flow of electrons using engineered ... many properties of matter are still unclear. Now a ... of the exotic electronic properties in matter using optical ... Jacob is the co-lead author on a study of ...
    Cached Biology Technology:CardioInsight Announces Appointment of Jim Bullock as Chairman of the Board of Directors 2HemoShear to Present at Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) Conference 2
    (Date:4/21/2015)... , April 21, 2015 ... government policies are boosting access control systems market in ... According to a recently published report by TechSci Research ... ", the access control systems market in ... billion by 2020.The access control systems market in the ...
    (Date:4/17/2015)... , April 17, 2015 ... security concerns, and technological advancement to drive biometric ... until 2020   According to ... Arabia Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems market ... projected to register growth at CAGR of over ...
    (Date:4/13/2015)... NEW YORK , April 13, 2015 /PRNewswire/ ... study by TechSci Research, "Global Biometrics Market Forecast & ... to register a CAGR of around 14% till ... various governments for large scale implementation and review ... technology and launch of new products with greater ...
    Breaking Biology News(10 mins):Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
    ... prefer to wipe the venomous little varmints off the face of ... The reviled South American native that invaded the U.S. Sun Belt ... invicta and everywhere else as a painful pest in the grass, ... ardent fire ant fan and one of its foremost researchers for ...
    ... Grail of horticultural accomplishment would be grass that never grows ... suburban bliss -- and more -- seems plausible as scientists ... stature of plants. In addition to lawns that rarely require ... more fruitful crop plants such as rice, wheat, soybeans, and ...
    ... the U.S. have their heels pricked soon after birth ... "heel stick" tests identify rare metabolic disorders before they ... to the screening ?many states now test for 30 ... the June issue of Pediatrics, researchers from Children's Hospital ...
    Cached Biology News:Fire ants: Their true story told by the scientist who loves them 2Fire ants: Their true story told by the scientist who loves them 3No-mow grass may be coming to your yard soon 2No-mow grass may be coming to your yard soon 3Newborn screening can cause unnecessary parental stress 2Newborn screening can cause unnecessary parental stress 3
    Request Info...
    DNA polymerase I, large fragment...
    supplied with 10x reaction buffer...
    ... overproducer ATP: D-hexose 6- phosphotransferase/D-glucose-6-phosphate: ... unit of HK will phosphorylate ... 1 min at 25C at ... G6P-DH will oxidize 1 mol ...
    Biology Products: